Craft

Medpace

Stock Price

$329.8

2024-10-29

Market Capitalization

$10.2 B

2024-10-29

Revenue

$1.9 B

FY, 2023

Medpace Summary

Company Summary

Overview
Medpace Holdings is a clinical contract research organization (CRO). It specializes in clinical trial management and monitoring, pharmacovigilance, regulatory affairs and medical writing, biostatistics services, etc. The company caters to the biotechnology, medical device, and pharmaceutical sectors.
Type
Public
Status
Active
Founded
1992
HQ
Cincinnati, OH, US | view all locations
Website
https://www.medpace.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • August Troendle

    August Troendle, Chief Executive Officer & Chairman

    • Jesse Geiger
    • Stephen Ewald

      Stephen Ewald, General Counsel, Chief Compliance Officer and Corporate Secretary

    • Kevin Brady

      Kevin Brady, Chief Financial Officer

    Operating MetricsView all

    Backlog

    $2.7B
    28.8%

    Q3, 2023

    Countries

    40

    Q3, 2023

    Facility Space, sq. ft.

    600K

    FY, 2022

    LocationsView all

    37 locations detected

    • Cincinnati, OH HQ

      United States

      5365 Medpace Way

    • Denver, CO

      United States

      717 17th Street, Suite 500

    • Irving, TX

      United States

      Building A, 2120 West Walnut Hill Lane

    • Buenos Aires, CABA

      Argentina

      La Pampa 1512, 13th Floor

    • South Yarra, VIC

      Australia

      Level 11 Como Tower, 644 Chapel Street

    • Leuven, Vlaams Gewest

      Belgium

      Technologielaan 11

    and 31 others

    Medpace Financials

    Summary Financials

    Revenue (Q3, 2024)
    $533.3M
    Gross profit (Q3, 2024)
    $169.0M
    Net income (Q3, 2024)
    $96.4M
    Cash (Q3, 2024)
    $656.9M
    EBIT (Q3, 2024)
    $112.3M
    Enterprise value
    $9.7B

    Footer menu